Saturday, March 21, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Biden administration to buy 500 million Pfizer coronavirus vaccine doses to donate to the world

The Biden administration is buying 500 million doses of Pfizer’s coronavirus vaccine to donate to the world as the United States dramatically increases its efforts to help vaccinate more of the global population, three people familiar with the plans said Wednesday.

The first 200 million doses will be distributed this year, with the subsequent 300 million shared in the first half of next year. The doses will be distributed by Covax, the World Health Organization-backed initiative to share doses around the globe, and they will be targeted at low- and middle-income countries. Pfizer is selling the doses to the United States at a “not-for-profit” price, according to the people familiar with the deal, who spoke on the condition of anonymity to share details that were not yet public.

President Biden is slated to announce the plan this week at the Group of Seven meeting in Britain, where he is expected to be joined by Pfizer CEO Albert Bourla. The deal comes amid growing calls for the United States and other rich countries to play a more substantial role in boosting the global supply of coronavirus vaccines.

Source: Washington Post

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!